Effective phagocytosis and killing of Candida albicans via targeting Fcγ/RI (CD64) or FcαRI (CD89) on neutrophils

Journal of Infectious Diseases

Volumn 179, Issue 3, 1999, Pages 661-669

  Van Spriel, Annemiek B ^a   Van Den Herik Oudijk, Ingrid E ^a   Van Sorge, Nina M ^a   Vilé, Henriette A ^a   Van Strijp, Jos A G ^a   Van De Winkel, Jan G J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD64 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN FC FRAGMENT;

ANIMAL CELL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; FUNGICIDAL ACTIVITY; HOST RESISTANCE; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; MOUSE; NEUTROPHIL; NONHUMAN; NORMAL HUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN TARGETING; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD; CANDIDA ALBICANS; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; KINETICS; MICE; MICE, TRANSGENIC; NEUTROPHILS; PHAGOCYTOSIS; RECEPTORS, FC; RECEPTORS, IGG;

EID: 0033398577     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314643     Document Type: Article

References (40)

1. 1. Sternberg S. The emerging fungal threat. Science 1994;266:1632-4.
2. 2. Nolla-Salas J, Sitges-Serra A, León-Gil C, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med 1997;23:23-30.
3. 3. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-5.
4. 4. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-15.
5. 5. Bodey GP, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992;11:99-109.
6. 6. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993;17:705-7.
7. 7. Kerst JM, van de Winkel JGJ, Evans AH et al. Granulocyte colony-stimulating factor induces hFcγRI (CD64 antigen)-positive neutrophils via an effect on myeloid precursor cells. Blood 1993;81:1457-64.
8. 8. Allen RC, Stevens PR, Price TH, Chatta GS, Dale DC. In vivo effects of recombinant human granulocyte colony-stimulating factor on neutrophil oxidative functions in normal human volunteers. J Infect Dis 1997;175: 1184-92.
9. 9. Dale DC, Liles WC, Summer WR, Nelson S. Review: granulocyte colony-stimulating factor - role and relationships in infectious diseases. J Infect Dis 1995;172:1061-75.
10. 10. Greenberg S, Silverstein SC. Phagocytosis. In: Paul WE, ed. Fundamental immunology. 3rd ed. New York: Raven Press, 1993:941-64.
11. 11. Stahl PD. The mannose receptor and other macrophage lectins. Curr Opin Immunol 1992;4:49-52.
12. 12. Repp R, Valerius T, Sendler A, et al. Neutrophils express the high affinity receptor for IgG (FcγR1, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood 1991;78:885-9.
13. 13. Guyre PM, Morganelli PM, Miller R. Recombinant immune interferon increases immunoglobulin Fc receptors on cultured human mononuclear phagocytes. J Clin Invest 1983;72:393-7.
14. 14. Morton HC, van Egmond M, van de Winkel JGJ. Structure and function of human IgA Fc receptors (FcαR). Crit Rev Immunol 1996;16:423-40.
15. 15. Van Vugt MJ, Heijnen IAFM, Capel PJA, et al. FcR γ-chain is essential for both surface expression and function of human FcγRI (CD64) in vivo. Blood 1996;87:3593-9.
16. 16. Van de Winkel JGJ, Capel PJA, eds. Human IgG Fc receptors. 1st ed. Austin, TX: RG Landes, 1996.
17. 17. Casadevall A. Minireview: antibody immunity and invasive fungal infections. Infect Immun 1995;63:4211-8.
18. 18. Levitz SM. Overview of host defenses in fungal infections. Clin Infect Dis 1992;14:S37-42.
19. 19. Carrow EW, Hector RF, Domer JE. Immunodeficient CBA/N mice respond effectively to Candida albicans. Clin Immunol Immunopathol 1984;33: 371-80.
20. 20. Mahanty S, Greenfield RA, Joyce WA, Kincade PW. Inoculation candidiasis in a murine model of severe combined immunodeficiency syndrome. Infect Immun 1988;56:3162-6.
21. 21. Jensen J, Warner T, Balish E. Resistance of SCID mice to Candida albicans administered intravenously or colonizing the gut: role of polymorpho-nuclear leukocytes and macrophages. J Infect Dis 1993;167:912-9.
22. 22. Van de Winkel JGJ, Bast B, de Gast GC. Immunotherapeutic potential of bispecific antibodies. Immunol Today 1997;18:562-4.
23. 23. Fanger MW, ed. Bispecific antibodies. 1st ed. Austin, TX: RG Landes, 1995.
24. 24. Heijnen IAFM, van Vugt MJ, Fanger NA, et al. Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest 1996;97:331-8.
25. 25. Leijh PCJ, van den Barselaar MT, van Furth R. Kinetics of phagocytosis and intracellular killing of Candida albicans by human granulocytes and monocytes. Infect Immun 1977;17:313-8.
26. 26. Nugent KM, Couchot KR. Effects of sublethal concentrations of amphotericin B on Candida albicans. J Infect Dis 1986;154:665-9.
27. 27. Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW. Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J Immunol 1989;143:1650-5.
28. 28. Monteiro RC, Cooper MD, Kubagawa H. Molecular heterogeneity of Fcα receptors detected by receptor-specific monoclonal antibodies. J Immunol 1992;148:1764-70.
29. 29. Lefkowitz SS, Gelderman MP, Lefkowitz DL, Moguilevsky N, Bollen A. Phagocytosis and intracellular killing of Candida albicans by macrophages exposed to myeloperoxidase. J Infect Dis 1996;173:1202-7.
30. 30. Maródi L, Forehand JR, Johnston RB. Mechanisms of host defense against Candida species. II. Biochemical basis for the killing of Candida by mononuclear phagocytes. J Immunol 1991;146:2790-4.
31. 31. Thornton BP, Vetvicka V, Pitman M, Goldman RC, Ross GD. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 1996;156: 1235-46.
32. 32. Matsumoto M, Matsubara S, Matsuno T, et al. Protective effect of human granulocyte colony-stimulating factor on microbial infection in neutropenic mice. Infect Immun 1987;55:2715-20.
33. 33. Kullberg BJ, Netea MG, Curfs JHAJ, Keuter M, Meis JFGM, van der Meer JWM. Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in non-neutropenic mice. J Infect Dis 1998;177:175-81.
34. 34. Roilides E, Holmes A, Blake C, Pizzo PA, Walsh TJ. Effects of granulocyte colony-stimulating factor and interferon-γ on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J Leukoc Biol 1995;57:651-6.
35. 35. Liles WC, Huang JE, van Burik JAH, Bowden RA, Dale DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis 1997;175:1012-5.
36. 36. Bober LA, Grace MJ, Pugliese-Sivo C, et al. The effect of GM-CSF and G-CSF on human neutrophil function. Immunopharmacology 1995;29: 111-9.
37. 37. Lechner AJ, Lamprech KE, Potthoff LH, Tredway TL, Matuschak GM. Recombinant GM-CSF reduces lung injury and mortality during neutropenic Candida sepsis. Am J Physiol 1994;266:L561-8.
38. 38. Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, et al. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 1993;82:1422-7.
39. 39. Weisbart RH, Kacena A, Schuh A, Golde DW. GM-CSF induces human neutrophil IgA-mediated phagocytosis by IgA Fc receptor activation mechanism. Nature 1988;332:647-8.
40. 40. Deo YM, Graziano RF, Repp R, van de Winkel JGJ. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol Today 1997;18:127-35.